Literature DB >> 8792388

Serum insulin-like growth factors and their binding proteins in children with end-stage renal disease.

B Tönshoff1, W F Blum, O Mehls.   

Abstract

Serum levels of insulin-like growth factor-I (IGF-I), IGF-II, and IGF binding protein-1 (IGFBP-1), IGFBP-2, and IGFBP-3 were measured in 54 children with end-stage renal disease (ESRD). The results were compared with their respective age-dependent normal ranges. IGFs and IGFBPs were quantified by specific radioimmunoassay. Serum IGF-I in children with ESRD tended to cluster in the low-normal range. Mean age-related serum IGF-I levels were slightly, but significantly decreased (-1.08 +/- 0.17 SDS). In view of the prevailing elevated growth hormone levels in ESRD, these serum IGF-I levels must be interpreted as inadequately low. In contrast to IGF-I, individual serum IGF-II levels were either in the upper-normal range or clearly elevated. Mean age-related IGF-II (1.09 +/- 0.15 SDS) was slightly, but significantly elevated. Mean age-related IGFBP-1 serum levels (2.20 +/- 0.10 SDS) were moderately increased, while mean age-related serum IGFBP-2 (5.65 +/- 0.36) and IGFBP-3 levels (3.60 +/- 0.19) were markedly elevated. Affinity cross-linking of 125iodine-IGF-II to sera from patients with ESRD and immunoprecipitation with a specific antiserum showed that low molecular weight IGFBP-3 fragments in ESRD serum are capable of binding IGF. In patients with ESRD, a rapid and persistent decline of immunoreactive IGFBP-3 in response to restoration of renal function by renal transplantation was observed. This finding indicates that renal dysfunction contributes to high immunoreactive IGFBP-3 levels in ESRD. In conclusion, the imbalance between normal total IGF levels and the excess of IGFBPs in ESRD is likely to play a role in growth failure in these children.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8792388     DOI: 10.1007/bf00866755

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  30 in total

1.  Proteases acting on IGFBPs: their occurrence and physiological significance.

Authors:  J M Holly; D C Claffey; S C Cwyfan-Hughes; V J Frost; M E Yateman
Journal:  Growth Regul       Date:  1993-03

Review 2.  IGF binding protein-3 and the acid-labile subunit: formation of the ternary complex in vitro and in vivo.

Authors:  R C Baxter
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

3.  The 25-kilodalton insulin-like growth factor (IGF)-binding protein inhibits both basal and IGF-I-mediated growth of chick embryo pelvic cartilage in vitro.

Authors:  W M Burch; J Correa; J E Shively; D R Powell
Journal:  J Clin Endocrinol Metab       Date:  1990-01       Impact factor: 5.958

4.  Characterization of insulin-like growth factor-binding proteins in human serum from patients with chronic renal failure.

Authors:  F Liu; D R Powell; R L Hintz
Journal:  J Clin Endocrinol Metab       Date:  1990-03       Impact factor: 5.958

5.  Insulin-like growth factor-binding protein (IGF-BP) inhibition of granulosa cell function: effect on cyclic adenosine 3',5'-monophosphate, deoxyribonucleic acid synthesis, and comparison with the effect of an IGF-I antibody.

Authors:  T A Bicsak; M Shimonaka; M Malkowski; N Ling
Journal:  Endocrinology       Date:  1990-04       Impact factor: 4.736

6.  A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency.

Authors:  W F Blum; M B Ranke; K Kietzmann; E Gauggel; H J Zeisel; J R Bierich
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

7.  Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia.

Authors:  W F Blum; M B Ranke; K Kietzmann; B Tönshoff; O Mehls
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

8.  Somatomedin inhibitor in uremia.

Authors:  L S Phillips; A C Fusco; T G Unterman; F del Greco
Journal:  J Clin Endocrinol Metab       Date:  1984-10       Impact factor: 5.958

Review 9.  Acquired growth hormone resistance in patients with hypercatabolism.

Authors:  J Bentham; J Rodriguez-Arnao; R J Ross
Journal:  Horm Res       Date:  1993

10.  A specific radioimmunoassay for insulin-like growth factor II: the interference of IGF binding proteins can be blocked by excess IGF-I.

Authors:  W F Blum; M B Ranke; J R Bierich
Journal:  Acta Endocrinol (Copenh)       Date:  1988-07
View more
  11 in total

1.  Growth in children with chronic kidney disease: 13 years follow up study.

Authors:  Petar Salević; Pavle Radović; Nataša Milić; Radovan Bogdanović; Dušan Paripović; Aleksandra Paripović; Emilija Golubović; Biljana Milosević; Bilsana Mulić; Amira Peco-Antić
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

Review 2.  Longitudinal growth in children following kidney transplantation: from conservative to pharmacological strategies.

Authors:  Tim Ulinski; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2006-05-10       Impact factor: 3.714

Review 3.  Growth hormone/insulin-like growth factor system in children with chronic renal failure.

Authors:  Burkhard Tönshoff; Daniela Kiepe; Sonia Ciarmatori
Journal:  Pediatr Nephrol       Date:  2005-02-04       Impact factor: 3.714

Review 4.  Etiology and treatment of growth retardation in children with chronic kidney disease and end-stage renal disease: a historical perspective.

Authors:  Richard N Fine
Journal:  Pediatr Nephrol       Date:  2009-12-24       Impact factor: 3.714

5.  Growth hormone in chronic renal disease.

Authors:  Vishal Gupta; Marilyn Lee
Journal:  Indian J Endocrinol Metab       Date:  2012-03

Review 6.  Growth hormone axis in chronic kidney disease.

Authors:  Shefali Mahesh; Frederick Kaskel
Journal:  Pediatr Nephrol       Date:  2007-08-05       Impact factor: 3.714

7.  IGFBP2 is a biomarker for predicting longitudinal deterioration in renal function in type 2 diabetes.

Authors:  Ram P Narayanan; Bo Fu; Adrian H Heald; Kirk W Siddals; Robert L Oliver; Julie E Hudson; Antony Payton; Simon G Anderson; Anne White; William E R Ollier; J Martin Gibson
Journal:  Endocr Connect       Date:  2012-10-24       Impact factor: 3.335

8.  Low Insulin-Like Growth Factor-1 Level in Obesity Nephropathy: A New Risk Factor?

Authors:  Ioana Bancu; Maruja Navarro Díaz; Assumpta Serra; Marisa Granada; Dolores Lopez; Ramon Romero; Josep Bonet
Journal:  PLoS One       Date:  2016-05-03       Impact factor: 3.240

9.  A Suggested Role of Human Growth Hormone in Control of the COVID-19 Pandemic.

Authors:  Mohamed Hamdy Elkarow; Amr Hamdy
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-09       Impact factor: 5.555

10.  Summary of Expert Opinion on the Management of Children With Chronic Kidney Disease and Growth Failure With Human Growth Hormone.

Authors:  Marco Cappa; Mohamad Maghnie; Vincenza Carbone; Laura Chioma; Carmela Errichiello; Claudia Giavoli; Mario Giordano; Laura Guazzarotti; Antonella Klain; Giovanni Montini; Luisa Murer; Maria Parpagnoli; Carmine Pecoraro; Sabino Pesce; Enrico Verrina
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-02       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.